Australia is entering a decisive phase in medical device regulatory reform overseen by the Therapeutic Goods Administration (TGA) with the staged implementation of the Australian Unique Device Identification Database (AusUDID).
While many industry professionals are already familiar with Unique Device Identification (UDI) as a global concept, AusUDID is where that concept becomes operational in Australia.
With mandatory compliance deadlines commencing in July 2026, this article provides a clear understanding of what AusUDID is, why it matters, who is affected, and how it relates to UDI more broadly.
UDI and AusUDID: Understanding the Distinction
UDI is a globally harmonised system that assigns a unique identifier to medical devices, enabling precise identification across the entire device lifecycle. A UDI comprises two components:
- the UDI‑Device Identifier (UDI‑DI), a fixed code identifying a specific device model and packaging level, and
- the UDI‑Production Identifier (UDI‑PI), which captures variable production data such as lot number, serial number, or expiry date.
UDIs are issued by TGA‑accredited agencies supporting international standards across regulatory jurisdictions. These are GS1, Health Industry Business Communication Council (HIBCC), or International Council of Commonality in Blood Banking Automation (ICCBBA), and UDIs must appear on device labels and applicable packaging in both human‑readable and machine‑readable formats.
AusUDID is not the identifier itself. It is the national database operated by the TGA that stores UDI‑DIs and associated reference data for medical devices supplied in Australia. Each AusUDID record links device identification data to Australian regulatory approvals, making UDI usable within Australia’s regulatory, supply‑chain, and clinical environments.
Why AusUDID is being implemented
The primary objective of AusUDID is to strengthen patient safety. By enabling unambiguous device identification, UDI supports faster and more targeted recalls, improved adverse event reporting, and more effective post‑market surveillance. When safety issues arise, regulators and healthcare providers can more quickly identify affected products, locate them within supply chains or clinical settings, and prevent further use.
AusUDID also supports regulatory transparency and system efficiency. It provides a single, authoritative source of device identification information that can be accessed by sponsors, healthcare professionals, regulators, clinical quality registries, and the public. Importantly, the database does not store patient data or commercially confidential information, balancing transparency with appropriate safeguards.
Australia’s approach aligns with international guidance from the International Medical Device Regulators Forum (IMDRF), helping manufacturers manage global UDI obligations while meeting local regulatory requirements.
Key Data Elements Captured in AusUDID
At the core of AusUDID is a structured set of reference data aligned with IMDRF standards and tailored to Australian regulatory needs. These data elements ensure that each device can be accurately identified, authorised, and monitored throughout its lifecycle.
Each AusUDID record includes the UDI‑DI, which uniquely identifies a device model and its packaging level. Different packaging configurations may have different DIs. UDI‑DIs are issued by the accredited agencies leveraging global standards such as GS1 (typically encoded as a GTIN), HIBCC, or ICCBBA codes.
AusUDID also captures Australian sponsor details. The sponsor is the legal entity responsible for supplying the device in Australia and is accountable for submitting and maintaining accurate data in AusUDID. Sponsor information is recorded alongside device data and linked to the relevant ARTG inclusion.
Additional data elements include the brand name and model information exactly as shown on the device label, enabling healthcare providers and supply‑chain users to reliably match database records to the physical product. Each record also includes the Global Medical Device Nomenclature (GMDN) code and term, which define the device type and support regulatory grouping and post‑market surveillance.
Critically, every UDI‑DI record in AusUDID is linked to the corresponding inclusion in the Australian Register of Therapeutic Goods (ARTG). This confirms that the device is authorised for supply in Australia and anchors UDI data within the existing regulatory framework.
Together, these data elements make AusUDID more than a technical repository. They form the foundation for traceability, regulatory oversight, and system‑wide use of UDI across the healthcare sector.
When Compliance Becomes Mandatory
Australia’s UDI framework came into legal effect in March 2025, when AusUDID became operational. Since then, sponsors and manufacturers have been able to submit data on a voluntary basis to prepare for mandatory compliance.
Mandatory requirements are being introduced in phases based on device risk. From 1 July 2026, UDI labelling and AusUDID data submission become mandatory for high‑risk Class III and Class IIb medical devices. Lower‑risk medical devices and in vitro diagnostic devices will follow in subsequent stages, with full implementation extending to 2030.
This staged rollout prioritises patient safety while giving industry time to adapt labelling, systems, and data governance processes.
Who Needs to Act—and Why it Matters Now
Legal compliance obligations rest primarily with manufacturers and Australian sponsors. Manufacturers must assign UDIs using recognised standards and apply them correctly to labels or devices, while sponsors are responsible for submitting and maintaining accurate AusUDID records linked to the ARTG.
Healthcare organisations are not regulated entities under the UDI framework, but they are critical stakeholders. As UDI data becomes embedded in procurement, inventory, and clinical systems, healthcare providers will increasingly rely on AusUDID to support safe, efficient device use.
In simple terms, UDI provides the global identifier, and AusUDID makes it operational in Australia.
As mandatory deadlines approach, organisations that treat AusUDID as a strategic capability—rather than just a regulatory task—will be best positioned to manage risk, improve traceability, and support safer patient outcomes.
Contact us today to find out more about our certified digital solutions supporting AusUDID readiness.